Results 241 to 250 of about 578,456 (312)

Self‐Assembled Monolayers in p–i–n Perovskite Solar Cells: Molecular Design, Interfacial Engineering, and Machine Learning–Accelerated Material Discovery

Advanced Materials, EarlyView.
This review highlights the role of self‐assembled monolayers (SAMs) in perovskite solar cells, covering molecular engineering, multifunctional interface regulation, machine learning (ML) accelerated discovery, advanced device architectures, and pathways toward scalable fabrication and commercialization for high‐efficiency and stable single‐junction and
Asmat Ullah, Ying Luo, Stefaan De Wolf
wiley   +1 more source

Signatures of Edge States in Antiferromagnetic Van der Waals Josephson Junctions

Advanced Materials, EarlyView.
ABSTRACT The combination of superconductivity and magnetic textures leads to unconventional superconducting phenomena, including new correlated and topological phases. Van der Waals (vdW) materials emerge as a versatile platform for exploring the interplay between these two competing orders.
Celia González‐Sánchez, Ignacio Sardinero, Jorge Cuadra, Alfredo Spuri, José A. Moreno, Hermann Suderow, Elke Scheer, Pablo Burset, Angelo Di Bernardo, Rubén Seoane Souto, Eduardo J. H. Lee   +10 more
wiley   +1 more source

A framework for the definition and interpretation of the use of surrogate endpoints in interventional trials

EClinicalMedicine, 2023
Background Interventional trials that evaluate treatment effects using surrogate endpoints have become increasingly common. This paper describes four linked empirical studies and the development of a framework for defining, interpreting and reporting ...
Oriana Ciani, Martin Offringa, Alain Amstutz   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Surrogate endpoints in clinical trials: Definition and operational criteria

Statistics in Medicine, 1989
Ross L Prentice
exaly   +2 more sources

Challenge of Surrogate Endpoints

Southern Medical Journal, 2012
Surrogate endpoints are biomarkers that are intended to substitute for clinical endpoints. They have been used to find novel therapeutic targets, improve the statistical power and shorten the duration of clinical trials, and control the cost of conducting research studies.
James L, Furgerson, William N, Hannah, Jennifer C, Thompson   +2 more
openaire   +2 more sources

True endpoint reduction by surrogate endpoints

Communications in Statistics - Simulation and Computation, 2016
ABSTRACTThe use of surrogate endpoint, which is becoming widely popular now a days, was introduced in medical research to reduce the time of experiment required for the approval of a drug. Through cost cutting and time saving, the surrogate endpoints can bring profit to the medicine producers. We obtain the expression for the reduction of true samples,
Buddhananda Banerjee, Atanu Biswas
openaire   +1 more source

The Evaluation of Multiple Surrogate Endpoints

Biometrics, 2001
Summary.Surrogate endpoints are desirable because they typically result in smaller, faster efficacy studies compared with the ones using the clinical endpoints. Research on surrogate endpoints has received substantial attention lately, but most investigations have focused on the validity of using a single biomarker as a surrogate.
Xu, Jane, Zeger, Scott L.
openaire   +2 more sources

Should regulatory authorities approve drugs based on surrogate endpoints?

British medical journal, 2021
The aducanumab controversy is the latest example of surrogate endpoints failing to predict clinically important outcomes.
J. Lenzer, S. Brownlee
semanticscholar   +1 more source